
Apnimed fell 28.8% from $25.00 to $17.80, behind the S&P 500's −2.0%. Its worst day was Oct 6 (−14.3%), and its low came Nov 5 at $14.16.
Jul 31, 2026 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Apnimed closed at its highest level of the year, 30.2% above where the year started.
+2.5% · S&P 500 −0.5%
EPS of $3.92 beat the $-0.34 estimate on $12.1M revenue.
−2.5% · S&P 500 −0.5%
Story events cover the past 12 months · Times ET
Apnimed shares fell 14.3%, while the S&P 500 rose 0.5%.
−14.3%, the year's worst day · S&P 500 +0.5%
Apnimed closed at its lowest level of the year, 43.4% below where the year started.
−7.5% · S&P 500 −4.4%
EPS of $-1.05 missed the $-0.60 estimate on $2.5M revenue.
−3.8% · S&P 500 −1.9%
Where it ended: a close of $17.80 on Nov 17, 2026. Up next: Q4 2026 earnings on Feb 3, 2027 (EPS est. $-0.72).
Nothing in the past 12 months.
All APMD dividend historyReplay the year: the line draws itself and stops at each of the 5 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for APMD and SPY from Benzinga historical bars. Not investment advice.